by Barry101 | Nov 8, 2023 | Press Release
Data presented at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting Longitudinal comparison of biomarkers in tumor microenvironment showed a gradual, durable response over time in T lymphotactic CXCR3 ligands and cytolytic factors Phase 2 study...
by Barry101 | Nov 6, 2023 | Press Release
Highlights AIM’s Significant Momentum and Ongoing Achievement of Clinical and Regulatory Milestones Urges Shareholders to Protect AIM’s Progress by Voting for the Company’s Board of Directors and Discarding Any Proxy Materials from the Activist Group...
by Barry101 | Oct 30, 2023 | Press Release
OCALA, Fla., Oct. 30, 2023 — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including...
by Barry101 | Oct 17, 2023 | Press Release
OCALA, Fla., Oct. 17, 2023 — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM”) today announced it has entered into an agreement with Azenova, LLC (“Azenova”), a professional business development (BD) consulting firm, to support efforts to...
by Barry101 | Sep 22, 2023 | Press Release
OCALA, Fla., Sept. 22, 2023 — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced Chris McAleer, Ph.D., Scientific Officer of AIM will present at the 3rd Annual Marie Sklodowska-Curie Symposium on Cancer...
by Barry101 | Sep 11, 2023 | Press Release
Complete topline results confirm treatment was well tolerated, with promising clinical activity of pathologic complete response (pCR) + microinvasive residual disease (ypTmic) at 66%, comparable to pembrolizumab/neoadjuvant chemotherapy (NAC) Planned Phase 2 study in...
